Prognostication in palliative radiotherapy-ProPaRT: Accuracy of prognostic scores.
aggressiveness of care
outpatient palliative care
palliative radiotherapy
personalized palliative care
prognostication
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
22
07
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Prognostication can be used within a tailored decision-making process to achieve a more personalized approach to the care of patients with cancer. This prospective observational study evaluated the accuracy of the Palliative Prognostic score (PaP score) to predict survival in patients identified by oncologists as candidates for palliative radiotherapy (PRT). We also studied interrater variability for the clinical prediction of survival and PaP scores and assessed the accuracy of the Survival Prediction Score (SPS) and TEACHH score. Consecutive patients were enrolled at first access to our Radiotherapy and Palliative Care Outpatient Clinic. The discriminating ability of the prognostic models was assessed using Harrell's C index, and the corresponding 95% confidence intervals (95% CI) were obtained by bootstrapping. In total, 255 patients with metastatic cancer were evaluated, and 123 (48.2%) were selected for PRT, all of whom completed treatment without interruption. Then, 10.6% of the irradiated patients who died underwent treatment within the last 30 days of life. The PaP score showed an accuracy of 74.8 (95% CI, 69.5-80.1) for radiation oncologist (RO) and 80.7 (95% CI, 75.9-85.5) for palliative care physician (PCP) in predicting 30-day survival. The accuracy of TEACHH was 76.1 (95% CI, 70.9-81.3) and 64.7 (95% CI, 58.8-70.6) for RO and PCP, respectively, and the accuracy of SPS was 70 (95% CI, 64.4-75.6) and 72.8 (95% CI, 67.3-78.3). Accurate prognostication can identify candidates for low-fraction PRT during the last days of life who are more likely to complete the planned treatment without interruption.All the scores showed good discriminating capacity; the PaP had the higher accuracy, especially when used in a multidisciplinary way.
Sections du résumé
Background
UNASSIGNED
Prognostication can be used within a tailored decision-making process to achieve a more personalized approach to the care of patients with cancer. This prospective observational study evaluated the accuracy of the Palliative Prognostic score (PaP score) to predict survival in patients identified by oncologists as candidates for palliative radiotherapy (PRT). We also studied interrater variability for the clinical prediction of survival and PaP scores and assessed the accuracy of the Survival Prediction Score (SPS) and TEACHH score.
Materials and methods
UNASSIGNED
Consecutive patients were enrolled at first access to our Radiotherapy and Palliative Care Outpatient Clinic. The discriminating ability of the prognostic models was assessed using Harrell's C index, and the corresponding 95% confidence intervals (95% CI) were obtained by bootstrapping.
Results
UNASSIGNED
In total, 255 patients with metastatic cancer were evaluated, and 123 (48.2%) were selected for PRT, all of whom completed treatment without interruption. Then, 10.6% of the irradiated patients who died underwent treatment within the last 30 days of life. The PaP score showed an accuracy of 74.8 (95% CI, 69.5-80.1) for radiation oncologist (RO) and 80.7 (95% CI, 75.9-85.5) for palliative care physician (PCP) in predicting 30-day survival. The accuracy of TEACHH was 76.1 (95% CI, 70.9-81.3) and 64.7 (95% CI, 58.8-70.6) for RO and PCP, respectively, and the accuracy of SPS was 70 (95% CI, 64.4-75.6) and 72.8 (95% CI, 67.3-78.3).
Conclusion
UNASSIGNED
Accurate prognostication can identify candidates for low-fraction PRT during the last days of life who are more likely to complete the planned treatment without interruption.All the scores showed good discriminating capacity; the PaP had the higher accuracy, especially when used in a multidisciplinary way.
Identifiants
pubmed: 36052228
doi: 10.3389/fonc.2022.918414
pmc: PMC9425085
doi:
Types de publication
Journal Article
Langues
eng
Pagination
918414Informations de copyright
Copyright © 2022 Maltoni, Scarpi, Dall’Agata, Micheletti, Pallotti, Pieri, Ricci, Romeo, Tenti, Tontini and Rossi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):870-3
pubmed: 15708268
J Clin Oncol. 2013 Jan 1;31(1):80-7
pubmed: 23169520
J Clin Oncol. 2008 Dec 20;26(36):5863-9
pubmed: 19018082
J Med Imaging Radiat Oncol. 2020 Aug;64(4):570-579
pubmed: 32592442
Health Technol Assess. 2021 May;25(28):1-118
pubmed: 34018486
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):52-60
pubmed: 31682969
Support Care Cancer. 2020 Apr;28(4):1545-1546
pubmed: 31758320
Cancer. 2014 Jan 1;120(1):134-41
pubmed: 24122413
J Oncol Pract. 2019 Mar;15(3):e262-e270
pubmed: 30620629
J Pain Symptom Manage. 2021 Jun;61(6):1180-1187
pubmed: 33096217
PLoS One. 2016 Aug 25;11(8):e0161407
pubmed: 27560380
Cancer. 2010 Jul 1;116(13):3251-6
pubmed: 20564632
J Clin Oncol. 2004 Dec 1;22(23):4823-8
pubmed: 15570085
J Oncol Pract. 2014 Jul;10(4):e269-76
pubmed: 24756144
Radiother Oncol. 2015 May;115(2):264-71
pubmed: 25861831
Cancer Med. 2020 Aug;9(16):5781-5787
pubmed: 32592315
Eur J Cancer. 2021 Oct 11;158:27-35
pubmed: 34649086
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1291-302
pubmed: 12128132
Palliat Support Care. 2022 Apr;20(2):221-225
pubmed: 34134807
Support Care Cancer. 2016 Sep;24(9):3997-4004
pubmed: 27129839
PLoS One. 2021 Apr 28;16(4):e0249763
pubmed: 33909658
Ann Palliat Med. 2019 Apr;8(2):150-158
pubmed: 30525772
Lancet Oncol. 2016 Dec;17(12):e552-e559
pubmed: 27924753
Oncologist. 2012;17(3):446-54
pubmed: 22379068
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):280-7
pubmed: 18676092
JAMA. 1998 Jun 3;279(21):1709-14
pubmed: 9624023
World J Oncol. 2011 Aug;2(4):181-190
pubmed: 29147245
Int J Qual Health Care. 2005 Dec;17(6):505-9
pubmed: 15985505
BMC Med. 2017 Aug 2;15(1):139
pubmed: 28764757
J Clin Oncol. 2004 Jan 15;22(2):315-21
pubmed: 14722041
Support Care Cancer. 2019 Jun;27(6):1973-1984
pubmed: 30863893
J Pain Symptom Manage. 1999 Apr;17(4):240-7
pubmed: 10203876
J Clin Oncol. 2005 Sep 1;23(25):6240-8
pubmed: 16135490
Ann Palliat Med. 2016 Jan;5(1):22-9
pubmed: 26841812
J Pain Symptom Manage. 1999 Apr;17(4):231-9
pubmed: 10203875
J Clin Oncol. 2014 Sep 10;32(26):2913-9
pubmed: 25113773
Radiother Oncol. 2017 Nov;125(2):193-199
pubmed: 29050955
Anticancer Res. 2014 Feb;34(2):877-85
pubmed: 24511026
J Pain Symptom Manage. 2017 May;53(5):962-970.e10
pubmed: 28062344
BMJ Support Palliat Care. 2022 May;12(e1):e10-e20
pubmed: 32241958
Tumori. 2017 Jan 21;103(1):9-14
pubmed: 28009422